Description

Simple

Clinical

Overview

GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

Pharmacology

Indication

Investigated for use/treatment in hepatitis (viral, C).

Pharmacodynamic

Information currently not available.

Mechanism of action

The mechanism of action for GI-5005 (i.e. immune elimination of infected hepatic cells) may work synergistically in combination with the current or emerging standard of care, which directly inhibits viral replication, to more effectively eradicate hepatitis C virus from the liver. Additionally, this... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with GI-5005
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2-Methoxyethanol
The therapeutic efficacy of GI-5005 can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
The therapeutic efficacy of GI-5005 can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Abatacept.
Abetimus
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Abetimus.
Acteoside
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Acteoside.
Adalimumab
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Adalimumab.
Afelimomab
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Afelimomab.
Alclometasone
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alclometasone.
Aldesleukin
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Aldesleukin.
Aldosterone
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Aldosterone.
Alefacept
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept.
Alemtuzumab
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alemtuzumab.
Altretamine
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Altretamine.
Amcinonide
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Amcinonide.
Amsacrine
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Amsacrine.
Anakinra
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Apremilast
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Apremilast.
Arsenic trioxide
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Arsenic trioxide.
1 References
  1. 1 . Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC: Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007 Feb 9;25(8):1452-63. Epub 2006 Nov 10.PubMed: 17098335